1-5 of 5
Roma Yumul
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47

Matthew R. Levengood, Christopher M. Carosino, Xinqun Zhang, Sasha Lucas, David J. Ortiz, Lori Westendorf, Alice P. Chin, Arlan D. Martin, Abbie Wong, Shawna M. Hengel, Hao Sun, Weiping Zeng, Roma Yumul, Melissa M.C. Dominguez, Yufei Chen, Janet H. Zheng, Courtney A.B. Karlsson, Vivian H. Trang, Peter D. Senter, Shyra J. Gardai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF14.
https://doi.org/10.1158/1535-7163.MCT-24-0371
Published: 22 November 2024
View article titled, Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Open the PDF for Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47 in another window
Includes: Supplementary data
Journal Articles

SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications

Robert P. Lyon, Mechthild Jonas, Christopher Frantz, Esther S. Trueblood, Roma Yumul, Lori Westendorf, Christopher J. Hale, Jackie L. Stilwell, Narayana Yeddula, Katie M. Snead, Vineet Kumar, Gabriela I. Patilea-Vrana, Kerry Klussman, Maureen C. Ryan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1444–1453.
https://doi.org/10.1158/1535-7163.MCT-22-0817
Published: 01 December 2023
View article titled, SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Open the PDF for SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications in another window
Includes: Supplementary data
Journal Articles

Abstract C113: Discovery of a novel auristatin antibody drug conjugate drug linker with equal efficacy and reduced bone marrow toxicity compared to vedotin

Noah A Bindman, Roma Yumul, Erica E McKinney, Scott Blackburn, Nicole Blesie, Xinqun Zhang, Brendan Drouhard, Sarah Anderson, Calvin Neace, David Ortiz, KC Crowder, Nancy Everds, Chris Carosino, Forgivemore Magunda, Django Sussman, Esther Trueblood, Nicole M. Okeley, Peter Senter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C113.
https://doi.org/10.1158/1535-7163.TARG-23-C113
Published: 01 December 2023
View article titled, Abstract C113: Discovery of a novel auristatin antibody drug conjugate drug linker with equal efficacy and reduced bone marrow toxicity compared to vedotin
Journal Articles

Abstract C132: SGN-35T: A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas

Kevin J Hamblett, Steven Jin, Roma Yumul, Yufei Chen, John Kwon, Jessica Simmons, Clark Henderson, Hao Sun, Jason P Schrum, Andrea R Lim, Noah A Bindman, Melissa Conerly, Astrid Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C132.
https://doi.org/10.1158/1535-7163.TARG-23-C132
Published: 01 December 2023
View article titled, Abstract C132: SGN-35T: A novel CD30-directed antibody-drug conjugate for the treatment of lymphomas
Journal Articles

SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

Rebecca Mazahreh, Marsha L. Mason, John J. Gosink, Devra J. Olson, Robert Thurman, Christopher Hale, Lori Westendorf, Thomas A. Pires, Christopher I. Leiske, Markus Carlson, Liem T. Nguyen, Julia H. Cochran, Nicole M. Okeley, Roma Yumul, Steven Jin, Ivan J. Stone, Disha Sahetya, Albina Nesterova, Sean Allred, Kelly M. Hensley, Rachael Hu, Robert Lawrence, Timothy S. Lewis, Sharsti Sandall
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (4): 421–434.
https://doi.org/10.1158/1535-7163.MCT-22-0401
Published: 03 April 2023
View article titled, SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Open the PDF for SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models in another window
Includes: Supplementary data